Leerink Partnrs Has Negative Outlook of LENZ FY2025 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities research analysts at Leerink Partnrs dropped their FY2025 earnings estimates for LENZ Therapeutics in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($2.65) per share for the year, down from their previous estimate of ($2.40). The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics' FY2026 earnings at ($2.70) EPS and FY2028 earnings at $1.35 EPS.

Separately, HC Wainwright reiterated a "buy" rating and set a $38.00 price objective on shares of LENZ Therapeutics in a report on Thursday, November 7th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, LENZ Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $35.40.

LENZ Therapeutics Stock Performance

NASDAQ LENZ traded up $0.56 during mid-day trading on Friday, hitting $25.93. The company's stock had a trading volume of 40,833 shares, compared to its average volume of 165,476. The company's 50 day simple moving average is $29.28 and its 200 day simple moving average is $26.84. LENZ Therapeutics has a twelve month low of $14.42 and a twelve month high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same period in the prior year, the business posted ($1.33) earnings per share.

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp increased its position in shares of LENZ Therapeutics by 18.7% during the third quarter. State Street Corp now owns 289,154 shares of the company's stock valued at $6,865,000 after acquiring an additional 45,600 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at $3,308,000. Charles Schwab Investment Management Inc. raised its stake in shares of LENZ Therapeutics by 197.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock worth $2,929,000 after purchasing an additional 81,901 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of LENZ Therapeutics by 28.4% in the 2nd quarter. Renaissance Technologies LLC now owns 60,166 shares of the company's stock worth $1,040,000 after buying an additional 13,300 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in LENZ Therapeutics during the fourth quarter valued at about $1,270,000. Hedge funds and other institutional investors own 54.32% of the company's stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.